解读阿仑单抗关键III期试验中的淋巴细胞重建数据
该研究基于CARE-MS I和II试验的淋巴细胞亚群数据,分析阿仑单抗治疗复发型多发性硬化后的免疫重建特征。结果显示CD4+和CD8+ T细胞长期受抑,而CD19+ B细胞早期耗竭后出现未成熟B细胞过度重建,与药物抗体产生及继发性B细胞自身免疫相关,记忆B细胞长期耗竭可能解释疗效。
要点
- 阿仑单抗导致CD4+ T细胞持续深度耗竭,调节性T细胞和CD8+ T细胞也长期低于参考水平。
- CD19+ B细胞早期耗竭后出现未成熟B细胞过度重建,与继发性自身免疫相关。
- 记忆B细胞长期耗竭可能介导疗效,控制B细胞增殖或可减少继发性自身免疫。
核心结论
- 阿仑单抗治疗后CD19+ B细胞亚群快速重建而T细胞调节未恢复,影响安全性和疗效。
研究设计与样本
- 从欧洲药品管理局获取CARE-MS I和II关键III期试验的监管提交文件,提取淋巴细胞亚群和抗药抗体数据进行分析。
主要发现
- 阿仑单抗耗竭CD4+ T细胞超过95%,包括调节性细胞减少80%,CD8+ T细胞耗竭超过80%,且在整个试验期间持续低于参考水平。
- CD19+ B细胞初期耗竭超过85%,但未成熟B细胞出现180%的过度重建并随时间转换为成熟B细胞。
- 这些淋巴细胞动力学与阿仑单抗结合抗体和中和抗体的快速产生及继发性B细胞自身免疫的发生相关。
- B细胞过度重建掩盖了CD19+记忆B细胞的显著长期耗竭,后者可能介导多发性硬化疗效。
临床怎么用
- 监测阿仑单抗治疗后B细胞亚群重建动态,尤其关注未成熟B细胞过度增殖和抗药抗体形成。
- 控制B细胞增殖直至T细胞调节恢复,可能有助于限制继发性自身免疫。
局限性
- 数据来源于监管提交文件中的表格化数据,非原始个体水平分析。
- 研究为对既有试验数据的二次分析,未报告样本量等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell autoimmunities that limit use. These effects may be avoided through control of B-cell hyperproliferation. OBJECTIVE: To investigate whether the data describing the effect of alemtuzumab on lymphocyte subsets collected during the phase 3 trial program reveal mechanisms explaining efficacy and the risk for secondary autoimmunity with treatment of MS. DESIGN, SETTING, AND PARTICIPANTS: Lymphocyte reconstitution data from regulatory submissions of the pivotal Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I and II (CARE-MS I and II) trials were obtained from the European Medicines Agency via Freedom of Information requests. Data used in this study were reported from June 22 to October 12, 2016. MAIN OUTCOMES AND MEASURES: Tabulated data from T- and B-lymphocyte subset analysis and antidrug antibody responses were extracted from the supplied documents. RESULTS: Alemtuzumab depleted CD4+ T cells by more than 95%, including regulatory cells (-80%) and CD8+ T cells (>80% depletion), which remained well below reference levels throughout the trials. However, although CD19+ B cells were initially also depleted (>85%), marked (180% increase) hyperrepopulation of immature B cells occurred with conversion to mature B cells over time. These lymphocyte kinetics were associated with rapid development of alemtuzumab-binding and -neutralizing antibodies and subsequent occurrence of secondary B-cell autoimmunity. Hyperrepopulation of B cells masked a marked, long-term depletion of CD19+ memory B cells that may underpin efficacy in MS. CONCLUSIONS AND RELEVANCE: Although blockade of memory T and B cells may limit MS, rapid CD19+ B-cell subset repopulation in the absence of effective T-cell regulation has implications for the safety and efficacy of alemtuzumab. Controlling B-cell proliferation until T-cell regulation recovers may limit secondary autoimmunity, which does not occur with other B-cell-depleting agents.
引用
- Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol. 2017. PMID: 28604916. doi:10.1001/jamaneurol.2017.0676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。